Shortcuts 2023 2022 2021 2020 2018 2017 2016 2015 2013 2012 2011
Johnston, PV, Bellumkonda, L, Raval, AN, et al. Cardiac Remodeling after Intramyocardial Autologous Bone Marrow Mononuclear Cell Therapy for Ischemic Cardiomyopathy: 2-Year Echocardiography Results. Presented at Annual Meeting of American College of Cardiology; March 6, 2023.
Johnston, PV, Anderson, RD, Raval, AN, et al. Autologous Cell Therapy for HFrEF: Efficacy Outcomes at Two Years for the Roll-in Cohort of a Phase III Pivotal Trial. Presented at Annual Meeting of Heart Failure Society of America; September 30-October 3, 2022.
Allogeneic NK-1R+ MSCs in Development for Acute Respiratory Distress Syndrome Secondary to COVID 19
Miller L, et al. Women with Heart Failure in the CardiAMP Cell Therapy Trial. Presented at Annual Meeting Heart Failure Society of America Annual Conference; September 2021.
Anderson RD, et al. CardiAMP Cell Therapy Trial for Heart Failure: Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy System in Patients with NYHA Class II & III Ischemic Systolic Heart Failure, Heart Failure Society of America Annual Conference, September 2021.
Raval A, et al. High Doses of CD34+ Cells Delivered to Patients in the CardiAMP Cell Therapy Heart Failure Trial, European Society of Cardiology Heart Failure Annual Meeting, June 2021.
Raval, AN, Johnston, PV, Duckers, HJ, et al. Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasability results from CardiAMP heart failure roll-in cohort. Int J Cardiol. 2020 Oct 20; S0167-5273(20)33996-6
Raval, AN, Pepine, CJ. Clinical safety profile of transendocardial catheter injection systems: A plea for uniform reporting. Cardiovasc Revasc Med 2020 Jun 30; S1553-8389(20)30416-4.
Johnston, PV, Duckers, HJ, Raval, AN, Cook, TD, Traverse, JH, Abraham, WT, Altman, PA, Pepine, CJ. The CardiAMPHeart Failure Trial: Efficacy Outcomes from Roll-In Phase. Presented at the Annual Scientific Sessions of the American Heart Association, November 12, 2018.
Johnston P, Duckers H, Raval A, Cook TD, Pepine CJ. Not all stem cells are created equal: The case for prospective assessment of stem cell potency in the CardiAMP Heart Failure Trial. Circ Res 2018;123:944–46.
Johnston PV, Duckers HJ, Raval AN, Cook T, Traverse JH, Abraham WT, Altman PA, Pepine CJ. The CardiAMP™ Heart Failure Clinical Trial First Results from the Unblinded Roll-In Phase. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, September 24, 2018.
Duckers, HJ, Ravel AN, Pepine, CJ, Johnston, PV, Traverse JH, Emery, J, Miller, L, Abraham, WT, Altman, PA. Performance of Helix transendocardial biotherapeutic delivery system after 300 cases. Presented at the Annual Meeting of Transcatheter Cardiovascular Therapeutics, September 24, 2018.
Pepine, CJ, Raval, AN, Johnston, PV, Traverse, JH, Abraham, WT, Altman, PA. CardiAMP™ Heart Failure Trial Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using CardiAMP Cell Therapy System in Patients with Post Myocardial Infarction Heart Failure. Presented at Annual Meeting of Heart Failure Society of America. September 15-18, 2018.
Raval AN, Cook TD, Duckers HJ, Johnston PV, Traverse JH, Abraham WT, Altman PA, Pepine CJ. The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post–myocardial infarction heart failure: Trial rationale and study design, Am Heart J. 2018 Jul;201:141-148.
Mitsutake Y, Pyum WB, Rouy D, et al. Improvement of local cell delivery using Helix Transendocardial Delivery Catheter in a porcine heart. Int Heart J. 2017.
Bergmann MW, Heeger C, Jaquet K, Boosfeld C et al. Early Transendocardial Autologous Bone Marrow Injection Of Bone Marrow Derived Mononuclear Cells Following Ischemic Myocardial Events (the Alster - Helix Phase I Study), CRT 2016.
Wong Po Foo, C, Rouy, D, et al. The Transendocardial Autologous Cells in Ischemc Heart Failure Trial Bone Marrow Mononuclear Cells (TAC-HFT-BMC) Randomized Placebo Controlled Blinded Study. Poster presented at: World Conference for Regenerative Medicine; 2015 Oct 21-23.
Heldman AW, DiFede DL, Fishman JE et al. Transendocardial Mesenchymal Stem Cells and Mononuclear Bone Marrow Cells for Ischemic Cardiomyopathy The TAC-HFT Randomized Trial JAMA. 2013.282909.
Hare JM, Fishman, JE, Gerstenblith G, et al. Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy, The POSEIDON Randomized Trial, JAMA. 2012;308(22).
de la Fuente LM, Stertzer SH, Argentieri J, et al. Transendocardial autologous bone marrow in myocardial infarction induced heart failure, two year follow-up in an open-label phase I safety study (the TABBMI Study). Eurointervention: J of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the ESC. 2011 Nov;7(7):805-12.
Empowered Patient Podcast
Henry Ford Health System
CALL US NOW
EMAIL US NOW